Recently, capital risk appetite has declined, market fluctuations have increased significantly, and growth tracks such as innovative drugs have undergone major adjustments. In this context, a number of public funds and foreign-funded institutions have intensively gone south to continue to lay out leading stocks in innovative pharmaceuticals. A number of fund managers also emphasized in the recent three-quarter report that the next few years may be an important stage in reading out key clinical data for innovative drugs in China, promoting overseas licensing, and realizing commercial value.

Recently, capital risk appetite has declined, market fluctuations have increased significantly, and growth tracks such as innovative drugs have undergone major adjustments. In this context, a number of public funds and foreign-funded institutions have intensively gone south to continue to lay out leading stocks in innovative pharmaceuticals. A number of fund managers also emphasized in the recent three-quarter report that the next few years may be an important stage in reading out key clinical data for innovative drugs in China, promoting overseas licensing, and realizing commercial value.